Horizon SPAC II and SL Bio Announce Nasdaq Business Combination
Biotechnology
Definitive Agreement
Merger:
Jun 15, 2026
Industry:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Horizon Space Acquisition II Corp. Announces Business Combination Agreement with SL Bio Ltd.
New York, NY, May 12, 2025 – Horizon Space Acquisition II Corp. (HSPT), a special purpose acquisition company, and SL Bio Ltd., a clinical-stage biomedical company, have entered into a definitive business combination agreement. Upon completion, SL Science Holding Limited will be listed on Nasdaq.
... Read on — Members only
About SL Science Holding Ltd
SL Bio is a biomedical company focused on developing innovative cellular and gene therapies for cancer treatment and regenerative medicine. Leveraging proprietary technologies and strategic partnerships, the company is advancing next-generation immunotherapies and exosome-based products for both medical and consumer applications. SL Bio’s approach combines scientific expertise with a commitment to improving patient outcomes and addressing unmet needs in healthcare. SL Bio also offers ISO-certified, dermatologically tested cow milk-derived exosome-based products and plant extract products for skin and hair care, with commercial distribution in Asia.
More SLBT News
Biotechnology
Definitive Agreement
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.